Esketamine vs Magnesium: Post-Op Pain in Sinus Surgery

Introduction to the Trial

A recent randomized controlled trial published on May 1, 2026, in OpenAlex explored the efficacy of intravenous esketamine compared to magnesium sulfate in managing postoperative pain and negative emotions in patients undergoing endoscopic sinus surgery (ESS). The study involved 137 patients who were randomly assigned to receive either esketamine, magnesium sulfate, or a saline control.

Mechanism and Context

Both esketamine and magnesium sulfate function as N-methyl-D-aspartate (NMDA) receptor antagonists, a class of drugs known for their role in managing perioperative pain and psychological distress. In this study, patients received a loading dose of either esketamine or magnesium sulfate before surgery, followed by a continuous infusion until the surgery concluded. The efficacy was measured using the Hospital Anxiety and Depression Scale (HADS) and Self-rating Anxiety/Depression Scale (SAS/SDS) on postoperative days one and two.

Research Findings

The results indicated that both esketamine and magnesium sulfate were effective in reducing negative emotions and pain on the first postoperative day compared to the saline control. However, on the second postoperative day, esketamine demonstrated superior efficacy over magnesium sulfate. Additionally, patients in the esketamine and magnesium groups required less remifentanil, a potent opioid analgesic, highlighting their potential to reduce opioid consumption.

Implications for Perioperative Care

This study's findings could significantly influence perioperative pain management practices. The superior efficacy of esketamine on the second postoperative day suggests that it might offer benefits beyond its current psychiatric applications, potentially leading to broader use in surgical settings. This could prompt further research into optimizing dosing regimens and identifying specific patient populations that might benefit most from esketamine therapy.

Risks and Unknowns

While the trial results are promising, there are risks and unknowns that need to be addressed. The long-term effects of esketamine use in surgical settings remain unclear, and potential side effects, such as dissociation, need careful monitoring. Furthermore, the study's sample size, though adequate for initial findings, might not capture all potential adverse reactions or rare complications.

Future Directions

Looking forward, further studies are needed to confirm these findings across different surgical procedures and patient demographics. Additionally, research into the cost-effectiveness of esketamine compared to other analgesics could provide valuable insights for healthcare providers and policymakers. As the landscape of perioperative care evolves, esketamine may become a key component in multimodal pain management strategies.